Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025
Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025
Galera Therapeutics第三季度每股收益为0.33美元，超过了美元（0.40美元）的预期；现金、现金等价物和2840万美元的短期投资预计将在2025年之前为其运营费用和资本支出需求提供资金
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 45 percent increase over losses of $(0.60) per share from the same period last year.
Galera Therapeutics（纳斯达克股票代码：GRTX）公布季度每股亏损0.33美元，比分析师普遍估计的0.40美元（0.40美元）高出17.5％。这比去年同期每股亏损美元（0.60美元）增加了45％。